Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Integrin α10β1-Selected Mesenchymal Stem Cells Mitigate the Progression of Osteoarthritis in an Equine Talar Impact Model.

Delco ML., Goodale M., Talts JF., Pownder SL., Koff MF., Miller AD.

Animal Study with a reported sample of 8 on Osteoarthritis, Cartilage Damage, Ankle Injury, Immune Modulation, published in Am J Sports Med (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Am J Sports Med (2020)
Country
United States
Reported sample size
8
Source database
PubMed
PMID
32004077
DOI
10.1177/0363546519899087

Abstract (original English)

Early intervention with mesenchymal stem cells (MSCs) after articular trauma has the potential to limit progression of focal lesions and prevent ongoing cartilage degeneration by modulating the joint environment and/or contributing to repair. Integrin α10β1 is the main collagen type II binding receptor on chondrocytes, and MSCs that are selected for high expression of the α10 subunit have improved chondrogenic potential. The ability of α10β1-selected (integrin α10 high ) MSCs to protect cartilage after injury has not been investigated. To investigate integrin α10 high MSCs to prevent posttraumatic osteoarthritis in an equine model of impact-induced talar injury. Controlled laboratory study. Focal cartilage injuries were created on the tali of horses (2-5 years, n = 8) by using an impacting device equipped to measure impact stress. Joints were treated with 20 × 10 6 allogenic adipose-derived α10 high MSCs or saline vehicle (control) 4 days after injury. Synovial fluid was collected serially and analyzed for protein content, cell counts, markers of inflammation (prostaglandin E2, tumor necrosis factor α) and collagen homeostasis (procollagen II C-propeptide, collagen type II cleavage product), and glycosaminoglycan content. Second-look arthroscopy was performed at 6 weeks, and horses were euthanized at 6 months. Joints were imaged with radiographs and quantitative 3-T magnetic re

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsCartilage, ArticularCell DifferentiationChondrocytesChondrogenesisHorsesIntegrinsMesenchymal Stem CellsOsteoarthritis

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research